InsiderPulse| Date | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-29 | EVNIN LUKE | Director | Sale | 56.6K | $0.69 | $39K | 1.95M | View ↗ | |
| 2026-04-28 | EVNIN LUKE | Director | Sale | 95.4K | $0.73 | $70K | 2.01M | View ↗ | |
| 2026-04-27 | EVNIN LUKE | Director | Sale | 53.9K | $0.85 | $46K | 2.11M | View ↗ | |
| 2026-01-16 | EVNIN LUKE | Director | Sale | 38.8K | $0.54 | $21K | 2.16M | View ↗ | |
| 2026-01-15 | EVNIN LUKE | Director | Sale | 37.4K | $0.55 | $21K | 2.20M | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Collaboration revenue | $0-100.0% | $1.9M-90.5% | $19.9M+21.6% | $16.4M |
| Research and development | $44.8M-20.6% | $56.4M+35.1% | $41.8M-22.3% | $53.8M |
| General and administrative | $15.8M-16.8% | $19.0M+2.0% | $18.7M-0.1% | $18.7M |
| Total operating expenses | $60.7M-19.6% | $75.5M+24.9% | $60.4M-16.6% | $72.5M |
| Operating loss | -$60.7M+17.6% | -$73.6M-81.7% | -$40.5M+27.7% | -$56.1M |
| Interest income | $3.1M-53.4% | $6.7M-10.0% | $7.4M+288.7% | $1.9M |
| Interest expense | -$5.3M-13.3% | -$4.7M-48.3% | -$3.1M | $0 |
| Loss on extinguishment of debt | $0+100.0% | -$553K | $0 | — |
| Other income, net | $2.0M+25.1% | $1.6M | — | — |
| Total other (expense) income | -$145K-104.7% | $3.1M | — | — |
| Net loss | -$60.8M+13.7% | -$70.5M-88.7% | -$37.4M+30.6% | -$53.8M |
| Net loss per common share, basic (in usd per share) | -$1K+19.0% | -$2K | — | — |
| Net loss per common share, diluted (in usd per share) | -$1K+18.4% | -$2K | — | — |
| Weighted average common shares outstanding, basic (in shares) | $46.02B+6.2% | $43.33B+21.6% | $35.65B+23.5% | $28.86B |
| Weighted average common shares outstanding, diluted (in shares) | $46.81B+6.7% | $43.86B+23.0% | $35.65B+23.5% | $28.86B |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Werewolf Therapeutics GAAP EPS of -$0.20 beats by $0.14
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
Werewolf Therapeutics announces plan to explore strategic alternatives
Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives
Werewolf Therapeutics (HOWL) Eyes 2026 Catalysts Following FDA Guidance and Encouraging INDUKINE Results
Werewolf Therapeutics Announces Pipeline and Business Updates
Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know
Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Insmed Misses on Q3 Earnings, Stock Rises on Strong Brinsupri Uptake
Werewolf Therapeutics: Continuing To Advance And Show More Promise In Phase 1
Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space